Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M4,630Revenue $M71.9Net Margin (%)-113.8Z-Score12.9
Enterprise Value $M4,428EPS $-0.8Operating Margin %-97.3F-Score0
P/E(ttm))0Cash Flow Per Share $0Pre-tax Margin (%)-119.2Higher ROA y-yN
Price/Book11.310-y EBITDA Growth Rate %0Quick Ratio3.1Cash flow > EarningsN
Price/Sales60.85-y EBITDA Growth Rate %0Current Ratio3.7Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-15.5Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)1ROE % (ttm)-21.5Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M105ROI % (ttm)-110.7Gross Margin Increase y-yN

Gurus Latest Trades with XON

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
XONT Boone Pickens 2014-12-31 Buy 0.53%$16.61 - $28.02
($23.05)
$ 44.1048%New holding10,000
XONDavid Einhorn 2014-12-31 Sold Out -0.05%$16.61 - $28.02
($22.97)
$ 44.1048%Sold Out0
XONDavid Einhorn 2014-09-30 Reduce-0.06%$17.86 - $26.59
($21.29)
$ 44.1052%Reduce -47.39%197,278
XONDavid Einhorn 2014-06-30 Reduce-0.39%$15.3 - $25.93
($21.15)
$ 44.1052%Reduce -72.81%375,000
XONJean-Marie Eveillard 2014-06-30 Buy 0.04%$15.3 - $25.93
($21.15)
$ 44.1052%New holding661,564
XONDavid Einhorn 2014-03-31 Reduce-0.26%$22.5 - $36.82
($28.82)
$ 44.1035%Reduce -37.58%1,379,014
XONT Boone Pickens 2013-12-31 Sold Out -0.47%$17.65 - $25.5
($21.05)
$ 44.1052%Sold Out0
XONDavid Einhorn 2013-09-30 Buy 0.86%$21.36 - $29.7
($24.16)
$ 44.1045%New holding2,176,868
XONT Boone Pickens 2013-09-30 Buy 0.47%$21.36 - $29.7
($24.16)
$ 44.1045%New holding12,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

XON is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


XON: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
KIRK RANDAL JCEO, 10% Owner 2015-01-27Buy555,556$2766.7view
Reed Thomas D.Chief Science Officer 2014-05-13Buy640$15.6188.53view
Lehr Donald P.Chief Legal Officer 2014-05-13Buy1,850$15.99181.49view
KIRK RANDAL JCEO, 10% Owner 2014-05-13Buy65,173$15.19196.31view
Krishnan Krish SCOO 2014-05-09Buy20,900$14.21216.75view
KIRK RANDAL JCEO, 10% Owner 2014-05-09Buy67,333$15.16196.9view
Krishnan SumaSVP--Product Development 2014-05-09Buy20,900$14.21216.75view
Huang KellySVP-Consumer Sector 2014-05-09Buy3,200$15.78185.23view
Kasser Thomas R.SVP--Food Sector 2014-05-09Buy10,000$13.39236.15view
KIRK RANDAL JCEO, 10% Owner 2014-03-27Buy243,001$25.7275view

Press Releases about XON :

    Quarterly/Annual Reports about XON:

    News about XON:

    Articles On GuruFocus.com
    Bill Miller Identifies What Could Be The Stock of The Decade Feb 10 2015 
    5-Year Lows: American Eagle Outfitters, Intrexon Corp, Mack-Cali Realty Corp, and Weight Watchers In Apr 20 2014 
    Daniel Loeb Comments on Intrexon Corporation Jan 22 2014 
    Daniel Loeb Lags S&P But Top New Stocks Advance Jan 07 2014 
    David Einhorn’s New Stocks – TPX, XON, NVR Nov 14 2013 
    Weekly CEO Buys Highlight: XON, ARCP, FSFR, CNTY, RHP Aug 18 2013 


    More From Other Websites
    INTREXON CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Apr 23 2015
    OTC Markets Group Welcomes Newly Verified OTCQB Companies – April 23 Apr 23 2015
    Omnicare (OCR) Catches Eye: Stock Rises 5.2% - Tale of the Tape Apr 22 2015
    Intrexon Completes Acquisition of Okanagan Specialty Fruits Apr 20 2015
    Intrexon Completes Acquisition of Okanagan Specialty Fruits Apr 20 2015
    Fibrocell Science to Present at World Orphan Drug Congress USA 2015 Apr 17 2015
    Driving Sustainable Agriculture through Improved Qualities in Eucalyptus and Poplar Trees Apr 15 2015
    Soligenix Announces FDA Protocol Clearance of Pivotal Phase 3 Clinical Trial of SGX203 in Pediatric... Apr 14 2015
    MedAssets: A Strong Sell on Tepid View, Estimate Revision - Analyst Blog Apr 09 2015
    INTREXON CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Apr 07 2015
    INTREXON CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements... Apr 02 2015
    Biotech Stock Mailbag: Northwest Bio, Intrexon, Ziopharm Apr 02 2015
    INTREXON CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Apr 01 2015
    Intrexon Signs Cooperative Research and Development Agreement (CRADA) with the National Cancer... Apr 01 2015
    Intrexon Signs Cooperative Research and Development Agreement (CRADA) with the National Cancer... Apr 01 2015
    Synthetic Biologics' SYN-004 Clinical Data for Protection of Microbiome Selected for Poster... Apr 01 2015
    Intrexon-Merck KGaA Team Up for CAR-T Cancer Therapies - Analyst Blog Mar 31 2015
    Norcraft and Auspex are big market movers Mar 30 2015
    Norcraft and Auspex are big market movers Mar 30 2015
    This Small Biotech Got A Booster Shot On CAR-T Deal Mar 30 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK